Regenerative Medicine Companies Poised for Upside

INTERVIEW ON THE PRICE OF BUSINESS SHOW, MEDIA PARTNER OF THIS SITE.

Recently Kevin Price, Host of the nationally syndicated Price of Business Show, interviewed Dr. Mark Swaim.

On a recent Price of Business show, Host Kevin Price interviewed Dr. Mark Swaim about three technologies that could dramatically improve the lives of those suffering from neuromuscular diseases and conditions.

According to a statement, “As the biotech sector is going through an extraordinary period of innovation, many companies will fall by the wayside, but what companies will succeed and where can investors find value?

“Dr. Mark Swaim, Founder and editor-in-chief, BioPub, a small-cap biotech investing website with a global following, will discuss his top three regenerative medicine picks poised for significant growth.

“Swaim, an early advocate of some of the world’s leading biotechs before they were widely recognized with high stock valuations – (such as Aurinia Pharmaceuticals) will discuss his lead recommendations in this category.  They include Algernon Pharmaceuticals, Capricor Therapeutics Inc. and NervGen Pharma:

  1. Algernon Pharmaceuticals, a clinical stage pharmaceutical development company (CSE: AGN) (OTCQB: AGNPF) is developing a drug that clearly drives central nervous system (CNS) neuron regrowth past following cerebrovascular accident (CVA),” says Dr. Swaim.
  2. Capricor Therapeutics Inc., (NASDAQ: CAPR), is developing transformative exosome-based therapeutics for the treatment and prevention of inflammatory diseases,” says Dr. Swaim.  “I think the Cardiopsheres cellular therapeutics infusion will become first-line treatment approach for Duchenne muscular dystrophy (DMD) symptom control and life extension.”
  3. NervGen Pharma Corp.’s (TSX-V: NGEN) (OTCQX: NGENF) is in the process of developing NVG-291, a clinical stage candidate to treat spinal cord injuries, multiple sclerosis and Alzheimer’s disease, with preclinical functional data in many disease models based on mechanisms including nervous system regeneration, remyelination, plasticity, as well as autophagy and innate immune modulation. “NVG-291is a veritable pipeline in a drug, given new evidence from animal models and in vitro work that it may treat not only spinal cord injury with restoration of gait but also multiple sclerosis, Alzheimer’s disease, stroke, and other neurodegenerative diseases,” says Dr. Swaim.

 

“Dr. Swaim served on the faculties of Duke University Medical Center, University of Texas MD Anderson Cancer Center and the McGovern Medical School of University of Texas in Houston and was elected to fellowship in the American College of Physicians.”

LISTEN TO THE INTERVIEW IN ITS ENTIRETY HERE:

The Price of Business is one of the longest running shows of its kind in the country and is in markets coast to coast. The Host, Kevin Price, is a multi-award winning author, broadcast journalist, and syndicated columnist. Learn more about the show and its digital partners at www.PriceofBusiness.com (scroll down to the bottom of the page).

Leave a Reply

Your email address will not be published.

RSS
Follow by Email
YouTube
YouTube
LinkedIn
LinkedIn
Share